Prollenium Announces Leadership Transition
Prollenium Medical Technologies (“Prollenium” or “the Company”), a leading innovator in the aesthetic medical space, has announced a significant leadership change as Ario Khoshbin, its Founder and longstanding Chief Executive Officer, has decided to step down from his executive role. Mr. Khoshbin will continue to contribute to the company’s strategic direction through his position on the Board of Directors and remains a substantial shareholder.
This transition marks a pivotal moment for Prollenium, a company that has steadily grown its global footprint by developing and manufacturing innovative aesthetic solutions, including dermal fillers and other cutting-edge cosmetic products. As the founder, Khoshbin has been instrumental in shaping Prollenium’s evolution from a startup to a recognized force in the global aesthetics industry. Under his leadership, the company successfully launched products such as Revanesse®, which have gained notable traction in both North American and international markets.
A Legacy of Innovation and Growth
Mr. Khoshbin’s decision to step down comes after years of notable achievements at the helm of Prollenium. During his tenure, he spearheaded the development of a robust pipeline of aesthetic solutions rooted in scientific research and advanced manufacturing capabilities. His vision and leadership helped establish Prollenium as the only manufacturer of dermal fillers in North America—a key differentiator in a market dominated by overseas production.
“I am incredibly proud of what we have built at Prollenium,” said Mr. Khoshbin in a statement. “After years of leading this company through stages of innovation, growth, and market expansion, I believe now is the right time to step back from the CEO role and allow new leadership to guide the company into its next phase. I remain committed to supporting Prollenium as a Board member and investor and am confident in the direction we are heading.”
The Board of Directors at Prollenium has expressed deep appreciation for Mr. Khoshbin’s contributions, highlighting his critical role in building a strong foundation for the company’s future success.
Preparing for the Next Chapter
In light of Mr. Khoshbin’s departure from day-to-day operations, Prollenium has appointed Walter Geiger as interim Chief Executive Officer, effective immediately. Mr. Geiger brings with him a wealth of experience in the healthcare and aesthetics sectors, having served in numerous senior executive roles at major multinational corporations.
Most recently, Mr. Geiger served as Chairman of the Board at Cellese Regenerative Therapeutics, a biotechnology firm known for its advancements in skin and tissue regeneration. Before that, he held leadership roles at Galderma, where he served as President of the Global Consumer Products Business Unit. His resume also includes high-level positions at industry titans such as Procter & Gamble and Johnson & Johnson, where he oversaw large-scale operations across North America, Europe, and Asia.
“Prollenium’s success is deeply rooted in its commitment to high-quality product development, regulatory excellence, and continuous innovation,” said Mr. Geiger. “I am honored to join the company during this exciting time of transition and look forward to working with the Board, the executive team, and all employees to continue delivering on our strategic objectives and strengthening our position in the global aesthetics market.”
A Search for Long-Term Leadership
The Prollenium Board has commenced a formal search for a permanent Chief Executive Officer. In the interim, the company is confident that Mr. Geiger’s experience and strategic mindset will ensure a smooth transition and continued momentum.
“The addition of a CEO with fresh expertise and perspective will enable Prollenium to continue to realize its potential as a major player in the development and manufacturing of aesthetic products on the global stage,” said Justin Bateman, Chairman of the Board at Prollenium. “We are deeply grateful to Ario for his vision, dedication, and the solid foundation he has built over the years. As we move forward, our focus remains on accelerating product innovation, expanding our international presence, and delivering exceptional value to both our customers and shareholders.”
Reinforcing Global Competitiveness
The appointment of an executive with Mr. Geiger’s global experience signals Prollenium’s ambitions to further expand its influence in the aesthetics space. With the global medical aesthetics market projected to reach over $25 billion by the end of the decade, Prollenium is well-positioned to capitalize on growing consumer demand for minimally invasive cosmetic procedures.
Prollenium’s flagship Revanesse® line has already made significant inroads in the U.S. and Canadian markets, competing with established brands through a combination of scientific precision, patient satisfaction, and clinical performance. The company’s vertically integrated manufacturing capabilities in Vaughan, Ontario, allow it to maintain stringent quality control, accelerate time to market, and respond dynamically to evolving customer needs—advantages that are becoming increasingly valuable in a highly competitive global industry.
Commitment to Innovation and Quality
Looking ahead, Prollenium remains focused on advancing its research and development programs, investing in new technologies, and expanding its product pipeline to meet diverse patient and practitioner needs. Its continued emphasis on clinical validation, safety, and efficacy ensures that it meets the highest standards of regulatory compliance across markets.
In addition to expanding its core filler business, the company is exploring adjacent opportunities in regenerative aesthetics and combination therapies—areas that align with emerging trends and hold strong potential for long-term growth.
Confidence in the Future
As Prollenium navigates this leadership transition, stakeholders can expect continuity in the company’s core mission: to improve lives through science-backed aesthetic innovations. The Board’s decision to bring in Walter Geiger as interim CEO ensures that the company will benefit from steady guidance and experienced leadership while continuing the search for a permanent executive who shares Prollenium’s values and vision for the future.
“Prollenium is entering a new and exciting chapter, and I am thrilled to support this journey,” Mr. Geiger concluded. “Our commitment to excellence, innovation, and patient safety will continue to drive everything we do. I look forward to collaborating with the talented team at Prollenium as we continue to grow and evolve.
